Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 1;7(5):436-444.
doi: 10.1007/s11515-012-1194-2.

Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants

Affiliations

Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants

Priyanka Subrahmanyam et al. Front Biol (Beijing). .

Abstract

Natural killer T (NKT) cells comprise a small, but important T cell subset and are thought to bridge the innate and adaptive immune responses. The discovery of NKT cells and extensive research on their activating ligands have paved the way for modulation of these potent immunoregulatory cells in order to improve the outcome of various clinical conditions. Efforts to modulate NKT cell effector functions have ranged from therapy for influenza to anti-tumor immunotherapy. These approaches have also led to the use of NKT cell agonists such as α-Galactosylceramide (α-GalCer) and its analogs as vaccine adjuvants, an approach that is aimed at boosting specific B and T cell responses to a vaccine candidate by concomitant activation of NKT cells. In this review we will provide a comprehensive overview of the efforts made in using α-GalCer and its analogs as vaccine adjuvants. The diverse array of vaccination strategies used, as well as the role of NKT cell activating adjuvants will be discussed, with focus on vaccines against malaria, HIV, influenza and tumor vaccines. Collectively, these studies demonstrate the efficacy of NKT cell-specific agonists as adjuvants and further suggest that these compounds warrant serious consideration during the development of vaccination strategies.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing financial interest.

Figures

Figure 1
Figure 1. The Role of NKT cell agonists as vaccine adjuvants
NKT cells can bridge innate and adaptive immune responses. NKT cells recognize lipid antigen in the context of CD1d molecules. Following activation, NKT cells rapidly secrete cytokines (i.e., IFN-g) and can directly mediate cytotoxicity. Cytokine production by NKT cells can lead to the activation of NK cells, macrophages (Mac) and in combination with CD40/CD40L interactions lead to the maturation of dendritic cells (DC). Thus, the co-administration of an NKT cell agonist, such as alpha galactosylceramide, with a vaccine may be able to enhance the efficacy of the vaccine by augmenting the magnitude of humoral and antigen-specific T cell responses.

References

    1. Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D, Mussack T, Bruns C, Ruttinger D, Conrad C, Jauch KW, Endres S, Eigler A. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: Results of a pilot study. Cancer Immunol Immunother. 2011;60(8):1097–1107. - PMC - PubMed
    1. Blauvelt ML, Khalili M, Jaung W, Paulsen J, Anderson AC, Brian Wilson S, Howell AR. Alpha-S-GalCer: Synthesis and evaluation for iNKT cell stimulation. Bioorg Med Chem Lett. 2008;18(24):6374–6376. - PMC - PubMed
    1. Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, Taniguchi M, Hayakawa K, Kronenberg M. Selective ability of mouse CD1 to present glycolipids: Alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol. 1998;161(7):3271–3281. - PubMed
    1. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163(9):4647–4650. - PubMed
    1. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood. 2007;110(6):2013–2019. - PMC - PubMed

LinkOut - more resources